Cancer BiologybioRxivPreprint
In vivo screen identifies LXR agonism potentiates sorafenib killing of hepatocellular carcinoma
Morgan E. Preziosi, Adam M. Zahm, Alexandra M. Vázquez-Salgado…·Kirk J. Wangensteen
The paper identifies LXR agonism as a potential enhancer of sorafenib's efficacy in treating hepatocellular carcinoma through an in vivo genetic screen and mechanistic studies.
DOI 10.1101/668350